Differences in Ca 15-3 and Homocysteine Levels in Patients with Benign Tumor and Breast Cancer

More than 25% of women have complaints related to breast lumps during their lifetime and approximately 12% have breast cancer. Cancer antigen 15-3 and homocysteine can be used as biomarkers in breast cancer. Breast cancer produces pro-inflammatory cytokines that can lead to increased CA 15-3 levels...

Full description

Saved in:
Bibliographic Details
Main Authors: Mathink Toonov ANUGERAWATI, Indranila Kustarini SAMSURIA, I Edward Kurnia Setiawan LIMIJADI, Dwi RETNONINGRUM, Banundari RACHMAWATI
Format: Article
Language:English
Published: Bucharest College of Physicians 2024-03-01
Series:Modern Medicine
Subjects:
Online Access:https://medicinamoderna.ro/wp-content/uploads/2024/03/Differences-in-Ca-15-3-and-Homocysteine-Levels-in-Patients-with-Benign-Tumor-and-Breast-Cancer.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849305608398831616
author Mathink Toonov ANUGERAWATI
Indranila Kustarini SAMSURIA
I Edward Kurnia Setiawan LIMIJADI
Dwi RETNONINGRUM
Banundari RACHMAWATI
author_facet Mathink Toonov ANUGERAWATI
Indranila Kustarini SAMSURIA
I Edward Kurnia Setiawan LIMIJADI
Dwi RETNONINGRUM
Banundari RACHMAWATI
author_sort Mathink Toonov ANUGERAWATI
collection DOAJ
description More than 25% of women have complaints related to breast lumps during their lifetime and approximately 12% have breast cancer. Cancer antigen 15-3 and homocysteine can be used as biomarkers in breast cancer. Breast cancer produces pro-inflammatory cytokines that can lead to increased CA 15-3 levels and serum homocysteine levels. Objective: To investigate the differences in CA 15-3 and homocysteine levels between patients with benign tumors and breast cancer. Methods: Observational analytic study with a cross-sectional approach in 30 benign breast tumor patients and 31 breast cancer patients. Measurement of CA 15-3 levels using enzyme linked immunofluorescent assay (ELFA) and homocysteine using competitive enzyme linked immunosorbant assay (ELISA). Comparative tests used independent T test and Mann-Whitney test. The study was conducted in 2023 at Kariadi Hospital Semarang and Ken Saras Hospital Ungaran. Results: CA 15-3 levels in the benign breast tumor group had a median of 11.74 (2.00-40.00) U/mL, while the breast cancer group was 18.66 (7.22-168.97) U/mL (p = 0.001). Homocysteine levels in benign breast tumors had a median of 3.05 (0.10-11.50) µmol/L and in the breast cancer group was 9.90 (3.70-17.20) µmol/L (p = 0.0001). Conclusion: CA 15-3 and homocysteine levels were lower in benign breast tumor patients compared with breast cancer patients.
format Article
id doaj-art-04476bfde2e9468f90ce64c797859b09
institution Kabale University
issn 1223-0472
2360-2473
language English
publishDate 2024-03-01
publisher Bucharest College of Physicians
record_format Article
series Modern Medicine
spelling doaj-art-04476bfde2e9468f90ce64c797859b092025-08-20T03:55:23ZengBucharest College of PhysiciansModern Medicine1223-04722360-24732024-03-01311576610.31689/rmm.2024.31.1.57Differences in Ca 15-3 and Homocysteine Levels in Patients with Benign Tumor and Breast CancerMathink Toonov ANUGERAWATI0Indranila Kustarini SAMSURIA1https://orcid.org/0000-0001-8918-1626I Edward Kurnia Setiawan LIMIJADI2Dwi RETNONINGRUM3Banundari RACHMAWATI4https://orcid.org/0000-0002-9181-5832Clinical Pathology Department, Faculty of Medicine, Universitas Diponegoro, Jl. Dr. Sutomo 16-18, Randusari 50244, Semarang, IndonesiaClinical Pathology Department, Faculty of Medicine, Universitas Diponegoro, Jl. Dr. Sutomo 16-18, Randusari 50244, Semarang, IndonesiaClinical Pathology Department, Faculty of Medicine, Universitas Diponegoro, Jl. Dr. Sutomo 16-18, Randusari 50244, Semarang, IndonesiaClinical Pathology Department, Faculty of Medicine, Universitas Diponegoro, Jl. Dr. Sutomo 16-18, Randusari 50244, Semarang, IndonesiaClinical Pathology Department, Faculty of Medicine, Universitas Diponegoro, Jl. Dr. Sutomo 16-18, Randusari 50244, Semarang, IndonesiaMore than 25% of women have complaints related to breast lumps during their lifetime and approximately 12% have breast cancer. Cancer antigen 15-3 and homocysteine can be used as biomarkers in breast cancer. Breast cancer produces pro-inflammatory cytokines that can lead to increased CA 15-3 levels and serum homocysteine levels. Objective: To investigate the differences in CA 15-3 and homocysteine levels between patients with benign tumors and breast cancer. Methods: Observational analytic study with a cross-sectional approach in 30 benign breast tumor patients and 31 breast cancer patients. Measurement of CA 15-3 levels using enzyme linked immunofluorescent assay (ELFA) and homocysteine using competitive enzyme linked immunosorbant assay (ELISA). Comparative tests used independent T test and Mann-Whitney test. The study was conducted in 2023 at Kariadi Hospital Semarang and Ken Saras Hospital Ungaran. Results: CA 15-3 levels in the benign breast tumor group had a median of 11.74 (2.00-40.00) U/mL, while the breast cancer group was 18.66 (7.22-168.97) U/mL (p = 0.001). Homocysteine levels in benign breast tumors had a median of 3.05 (0.10-11.50) µmol/L and in the breast cancer group was 9.90 (3.70-17.20) µmol/L (p = 0.0001). Conclusion: CA 15-3 and homocysteine levels were lower in benign breast tumor patients compared with breast cancer patients.https://medicinamoderna.ro/wp-content/uploads/2024/03/Differences-in-Ca-15-3-and-Homocysteine-Levels-in-Patients-with-Benign-Tumor-and-Breast-Cancer.pdfbenign breast tumorbreast cancerca 15-3homocysteine
spellingShingle Mathink Toonov ANUGERAWATI
Indranila Kustarini SAMSURIA
I Edward Kurnia Setiawan LIMIJADI
Dwi RETNONINGRUM
Banundari RACHMAWATI
Differences in Ca 15-3 and Homocysteine Levels in Patients with Benign Tumor and Breast Cancer
Modern Medicine
benign breast tumor
breast cancer
ca 15-3
homocysteine
title Differences in Ca 15-3 and Homocysteine Levels in Patients with Benign Tumor and Breast Cancer
title_full Differences in Ca 15-3 and Homocysteine Levels in Patients with Benign Tumor and Breast Cancer
title_fullStr Differences in Ca 15-3 and Homocysteine Levels in Patients with Benign Tumor and Breast Cancer
title_full_unstemmed Differences in Ca 15-3 and Homocysteine Levels in Patients with Benign Tumor and Breast Cancer
title_short Differences in Ca 15-3 and Homocysteine Levels in Patients with Benign Tumor and Breast Cancer
title_sort differences in ca 15 3 and homocysteine levels in patients with benign tumor and breast cancer
topic benign breast tumor
breast cancer
ca 15-3
homocysteine
url https://medicinamoderna.ro/wp-content/uploads/2024/03/Differences-in-Ca-15-3-and-Homocysteine-Levels-in-Patients-with-Benign-Tumor-and-Breast-Cancer.pdf
work_keys_str_mv AT mathinktoonovanugerawati differencesinca153andhomocysteinelevelsinpatientswithbenigntumorandbreastcancer
AT indranilakustarinisamsuria differencesinca153andhomocysteinelevelsinpatientswithbenigntumorandbreastcancer
AT iedwardkurniasetiawanlimijadi differencesinca153andhomocysteinelevelsinpatientswithbenigntumorandbreastcancer
AT dwiretnoningrum differencesinca153andhomocysteinelevelsinpatientswithbenigntumorandbreastcancer
AT banundarirachmawati differencesinca153andhomocysteinelevelsinpatientswithbenigntumorandbreastcancer